Novel agents for the medical treatment of endometriosis

Current Opinion in Obstetrics and Gynecology

Volumn 26, Issue 4, 2014, Pages 243-252

  Platteeuw, Lieven ^a   D'Hooghe, Thomas ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Endometriosis; Estrogen or progesterone receptor modulators; Inflammation and angiogenesis; Medical treatment; Tissue invasion and kinase inhibitor

Indexed keywords

ACETYLCYSTEINE; ANASTROZOLE; ANGINEX; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ASOPRISNIL; CELECOXIB; CIGLITAZONE; ELAGOLIX; ELOCALCITOL; ENDOSTATIN; EXEMESTANE; GONADORELIN; LETROZOLE; METFORMIN; MIFEPRISTONE; OMEGA 3 FATTY ACID; ONAPRISTONE; PIOGLITAZONE; PLACEBO; PROGESTERONE RECEPTOR MODULATOR; RESVERATROL; RETINOIC ACID; ROFECOXIB; ROSIGLITAZONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TELAPRISTONE; ULIPRISTAL; UNINDEXED DRUG; VALDECOXIB; GESTAGEN; ORAL CONTRACEPTIVE AGENT;

ANGIOGENESIS; ARTHRALGIA; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIOSIS; FRACTURE; GASTROINTESTINAL SYMPTOM; GENE THERAPY; HEADACHE; HUMAN; HYPERBARIC OXYGEN; IMMUNOSTIMULATION; INFERTILITY; INFLAMMATION; LIVER TOXICITY; MENSTRUATION; NAUSEA; NIDATION; NONHUMAN; OSTEOPENIA; OSTEOPOROSIS; OVULATION; PAIN; PRIORITY JOURNAL; REVIEW; AGONISTS; ANIMAL; COMPLICATION; FEMALE; INFERTILITY, FEMALE; MOUSE; PATHOLOGY;

ANIMALS; CONTRACEPTIVES, ORAL, HORMONAL; ENDOMETRIOSIS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; INFERTILITY, FEMALE; MICE; PAIN; PROGESTINS;

EID: 84904062614     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0000000000000084     Document Type: Review

References (84)

1. Giudice LC, Kao LC. Endometriosis. Lancet 2004; 364:1789-1799.
2. Meuleman C, Vandenabeel B, Fieuws S, et al. High prevalence of endometriosis in infertile women with normal ovulation and normospermic partners. Fertil Steril 2009; 92:68-74.
3. Canis G, Donnez J, Guzick D, et al. Revised American Society for Reproductive Medicine classification of endometriosis. Fertil Steril 1997; 67:817-821.
4. Kennedy S, Bergqvist A, Chapron C, et al. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod 2005; 20:2698-2704.
5. Milingos S, Protopapas A, Kallipolitis G. Endometriosis in patients with chronic pelvic pain: is staging predictive of the efficacy of laparoscopic surgery in pain relief? Gynecol Obstet Invest 2006; 62:48-54.
6. Protopapas A, Giannoulis G, Chatzipapas I, et al. Posterior deep infiltrating endometriotic nodules: operative considerations according to lesion size, location, and geometry, during one's learning curve. ISRN Obstet Gynecol 2014; 20:853-902.
7. Dunselman GAJ, Vermeulen N, Becker C, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod 2014; 29:400-412.
8. Guo SW. Recurrence of endometriosis and its control. Human Reprod Update 2009; 15:441-461.
9. Pullen N, Birch CL, Douglas GJ. The translational challenge in the development of new and effective therapies for endometriosis: a review of confidence from published preclinical afficacy studies. Hum Reprod Update 2011; 17:791-802.
10. Krikun G, Hu Z, Osteen K. The immunoconjugate 'icon' targets aberrantly expressed endothelial tissue factor causing regression of endometriosis. Am J Pathol 2010; 176:1050-1056.
11. Brown J, Pan A, Hart RJ, et al. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev 2010; 8:CD008475.
12. Diamond M, Carr B, Dmowski W, et al. Elagolix treatment for endometriosisassociated pain: results from a phase 2, randomized, double-blind, placebocontrolled study. Reprod Sci 2014; 21:363?371.
13. Kulak J, Fischer C, Komm B, Taylor HS. Treatment with bazedoxifene, a selective estrogen receptor modulator, causes regression of endometriosis in a mouse model. Endocrinology 2011; 152:3226-32
14. Stratton P, Sinaii N, Segars J, et al. Return of chronic pelvic pain from endometriosis after raloxifene treatment: a randomized controlled trial. Obstet Gynecol 2008; 111:88-96.
15. Merviel P, Lourdel E, Sanguin S, et al. Interest of selective progesterone receptor modulators in endometriosis. Gynecol Obstet Fertil 2013; 41:524-528.
16. Repros Therapeutics Inc. Safety and efficacy study to evaluate proellex in the treatment of premenopausal women with symptomatic endometriosis [ClinicalTrials.gov (Internet)]. Bethesda, MD: National Library of Medicine; 2000;Available from: http://clinicaltrials.gov/show/NCT00556075 NLM Identifier:NCT00556075. [Accessed 25 August 2010]
17. Mei L, Bao J, Tang L, et al. A novel mifepristone-loaded implant for long-term treatment of endometriosis: in vitro and in vivo studies. Eur J Pharm Sci 2010; 39:421-427.
18. Kettel L, Murphy A, Morales A, et al. Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertil Steril 1996; 65:23-28.
19. Chwalisz MC, Perez D, DeManno D, et al. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev 2005; 26:423-438.
20. Stoeckemann K, Hegele-Hartung C, Chwalisz K. Effects of the progesterone antagonists onapristone (ZK 98299) and ZK 136799 on surgically induced endometriosis in intact rats. Hum Reprod 1995; 10:3264-3271.
21. Kyama CM, Debrock S, Mwenda JM, D'Hooghe TM. Potential involvement of the immune system in the development of endometriosis. Reprod Biol Endocrinol 2003; 2:123.
22. Bulun SE, Gurates B, Fang Z, et al. Mechanisms of excessive estrogen formation in endometriosis. J Reprod Immunol 2002; 55 (1-2):21-33.
23. Laudanski P, Charkiewicz R, Kuzmicki M, et al. Profiling of selected angiogenesis- related genes in proliferative eutopic endometrium of women with endometriosis. Eur J Obstet Gynecol Reprod Biol 2014; 172:85-92.
24. Rocha AL, Reis FM, Petraglia F. New trends for the medical treatment of endometriosis. Expert Opin Investig Drugs 2012; 21:905-919.
25. Cobellis L, Razzi S, De Simone S, et al. The treatment with a COX-2 specific inhibitor is effective in the management of pain related to endometriosis. Eur J Obstet Gynecol Reprod Biol 2004; 116:100-102.
26. Olivares C, Ricci A, Bilotas M, et al. The inhibitory effect of celecoxib and rosiglitazone on experimental endometriosis. Fertil Steril 2011; 96:428-433.
27. Olivares CN, Bilotas MA, Ricci AG, et al. Anastrozole and celecoxib for endometriosis treatment, good to keep them apart? Reproduction 2013; 145:119-126.
28. Novembri R, Luisi S, Carrarelli P, et al. Omega 3 fatty acids counteract IL-8 and prostaglandinE2 secretion induced by TNF-alpha in cultured endometrial stromal cells. J Endometriosis 2011; 3:34-39.
29. Gustafsson A, Kupershmidt I, Edlundh-Rose E, et al. Global gene expression analysis in time series following N-acetyl L-cysteine induced epithelial differentiation of human normal and cancer cells in vitro. BMC Cancer 2005; 7:75.
30. Porpora MG, Brunelli R, Costa G, et al. A promise in the treatment of endometriosis: an observational cohort study on ovarian endometrioma reduction by N-acetylcysteine. Evid Based Complement Alternat Med 2013; 2013:240702.
31. Aydin Y, Atis A, Uludag S, et al. Remission of endometriosis by hyperbaric oxygen treatment in rats. Reprod Sci 2011; 18:941-947.
32. Han J, Thompson P, Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signalling pathway. J Exp Med 1990; 172:391-394.
33. Lu D, Song H, Li Y, et al. Pentoxifylline for endometriosis. Cochrane Database Syst Rev 2012; 18:CD007677.
34. Takemura Y, Osuga Y, Yoshino O, et al. Metformin suppresses interleukin (IL)- 1beta-induced IL-8 production, aromatase activation, and proliferation of endometriotic stromal cells. J Clin Endocrinol Metab 2007; 92:3213-3218.
35. Oner G, Ozcelik B, Ozgun MT, et al. The effects of metformin and letrozole on endometriosis and comparison of the two treatment agents in a rat model. Hum Reprod 2010; 25:932-937.
36. Taylor HS, Osteen KG, Bruner-tran KL. Novel therapies targeting endometriosis. Reprod Sci 2011; 18:814-823.
37. Lebovic DI, Kir M, Casey CL. Peroxisome proliferator-activated receptorgamma induces regression of endometrial explants in a rat model of endometriosis. Fertil Steril 2004; 82 (Suppl 3):1008-1013.
38. Lebovic DI, Mwenda JM, Chai DC, et al. PPAR-gamma receptor ligand induces regression of endometrial explants in baboons: a prospective, randomized, placebo- and drug-controlled study. Fertil Steril 2007; 88 (4 Suppl): 1108-1119.
39. Lebovic DI, Mwenda JM, Chai DC, et al. Peroxisome proliferator-activated receptor-(gamma) receptor ligand partially prevents the development of endometrial explants in baboons: a prospective, randomized, placebo-controlled study. Endocrinology 2010; 151:1846-1852.
40. Wieser F, Wu J, Shen Z, et al. Retinoic acid suppresses growth of lesions, inhibits peritoneal cytokine secretion, and promotes macrophage differentiation in an immunocompetent mouse model of endometriosis. Fertil Steril 2012; 97:1430-1437.
41. Ozer H, Boztosun A, Açmaz G, et al. The efficacy of bevacizumab, sorafenib, and retinoic acid on rat endometriosis model. Reprod Sci 2013; 20:26-32.
42. Mariani M, Viganò P, Gentilini D, et al. The selective vitamin D receptor agonist, elocalcitol, reduces endometriosis development in a mouse model by inhibiting peritoneal inflammation. Hum Reprod 2012; 27:2010-2019.
43. D'Hooghe TM, Nugent NP, Cuneo S, et al. Recombinant human TNFRSF1A (r-hTBP1) inhibits the development of endometriosis in baboons: a prospective, randomized, placebo- and drug-controlled study. Biol Reprod 2006; 74:131-136.
44. Falconer H, Mwenda JM, Chai DC, et al. Treatment with anti-TNF monoclonal antibody (c5N) reduces the extent of induced endometriosis in the baboon. Hum Reprod 2006; 21:1856-1862.
45. Koninckx PR, Craessaerts M, Timmerman D, et al. Anti-TNF-alpha treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial. Hum Reprod 2008; 23:2017-2023.
46. Lu D, Song H, Shi G. Anti-TNF-a treatment for pelvic pain associated with endometriosis. Cochrane Database Syst Rev 2013; 28:CD008088.
47. Kats R, Metz CN, Akoum A. Macrophage migration inhibitory factor is markedly expressed in active and early-stage endometriotic lesions. J Clin Endocrinol Metab 2002; 87:883-889.
48. Khoufache K, Bazin S, Girard K, et al. Macrophage migration inhibitory factor antagonist blocks the development of endometriosis in vivo. PLoS One 2012; 7:e37264.
49. Pedretti M, Rancic Z, Soltermann A, et al. Comparative immunohistochemical staining of atherosclerotic plaques using F16, F8 and L19: three clinicalgrade fully human antibodies. Atherosclerosis 2010; 208:382-389.
50. Schwager K, Bootz F, Imesch P, et al. The antibody-mediated targeted delivery of interleukin-10 inhibits endometriosis in a syngeneic mouse model. Hum Reprod 2011; 26:2344-2352.
51. Dulak J, Jó zkowicz A. Antiangiogenic and anti-inflammatory effects of statins: relevance to anticancer therapy. Curr Cancer Drug Targets 2005; 5:579-594.
52. Nap AW, Dunselman GA, Griffioen AW, et al. Angiostatic agents prevent the development of endometriosis-like lesions in the chicken chorioallantoic membrane. Fertil Steril 2005; 83:793-795.
53. Becker CM, Sampson DA, Rupnick MA, et al. Endostatin inhibits the growth of endometriotic lesions but does not affect fertility. Fertil Steril 2005;84(Suppl 2): 1144-1155.
54. Nap AW, Griffioen AW, Dunselman GA, et al. Antiangiogenesis therapy for endometriosis. J Clin Endocrinol Metab 2004; 89:1089-1095.
55. Dabrosin C, Gyorffy S, Margetts P, et al. Therapeutic effect of angiostatin gene transfer in a murine model of endometriosis. Am J Pathol 2002; 161:909-918.
56. Becker CM, Wright RD, Satchi-Fainaro R, et al. A novel noninvasive model of endometriosis for monitoring the efficacy of antiangiogenic therapy. Am J Pathol 2006; 168:2074-2084.
57. Yilmaz B, Ozat M, Kilic S, et al. Atorvastatin causes regression of endometriotic implants in a rat model. Reprod Biomed Online 2010; 20:291-299.
58. Oktem M, Esinler I, Eroglu D, et al. High-dose atorvastatin causes regression of endometriotic implants: a rat model. Hum Reprod 2007; 22:1474-1480.
59. Bruner-Tran KL, Osteen KG, Duleba AJ. Simvastatin protects against the development of endometriosis in a nude mouse model. J Clin Endocrinol Metab 2009; 94:2489-2494.
60. Krikun G, Schatz F, Taylor H, Lockwood CJ. Endometriosis and tissue factor. Ann NY Acad Sci 2008; 1127:101-105.
61. Yoysungnoen P, Wirachwong P, Bhattarakosol P, et al. Effects of curcumin on tumor angiogenesis and biomarkers, COX-2 and VEGF, in hepatocellular carcinoma cell-implanted nude mice. Clin Hemorheol Microcirc 2006; 34:109-115.
62. Zhang Y, Cao H, Hu YY, et al. Inhibitory effect of curcumin on angiogenesis in ectopic endometrium of rats with experimental endometriosis. Int J Mol Med 2011; 27:87-94.
63. Hull ML, Charnock-Jones DS, Chan CL, et al. Antiangiogenic agents are effective inhibitors of endometriosis. J Clin Endocrinol Metab 2003; 88:2889-2899.
64. Rein DT, Schmidt T, Bauerschmitz G, et al. Treatment of endometriosis with a VEGF-targeted conditionally replicative adenovirus. Fertil Steril 2010; 93:2687-2694.
65. Novella-Maestre E, Carda C, Noguera I, et al. Dopamine agonist administration causes a reduction in endometrial implants through modulation of angiogenesis in experimentally induced endometriosis. Hum Reprod 2009; 24:1025-1035.
66. Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007; 356:29-38.
67. Delgado-Rosas F, Gómez R, Ferrero H, et al. The effects of ergot and nonergot-derived dopamine agonists in an experimental mouse model of endometriosis. Reproduction 2011; 142:745-755.
68. Gómez R, Abad A, Delgado F, et al. Effects of hyperprolactinemia treatment with the dopamine agonist quinagolide on endometriotic lesions in patients with endometriosis-associated hyperprolactinemia. Fertil Steril 2011; 95:882-888.
69. Guo SW. Nuclear factor-kappab (NF-kappaB): an unsuspected major culprit in the pathogenesis of endomtriosis that is still at large? Gynecol Obstet Invest 2007; 63:71-97.
70. Celik O, Hascalik S. Combating endometriosis by blocking proteasome and nuclear factor-κB pathways. Hum Reprod 2008; 23:2458-2465.
71. Leconte M, Nicco C, Ngô C, et al. The mTOR/AKT inhibitor temsirolimus prevents deep infiltrating endometriosis in mice. Am J Pathol 2011; 179:880-889.
72. Yoshino O, Osuga Y, Koga K, et al. FR 167653, a p38 mitogen-activated protein kinase inhibitor, suppresses the development of endometriosis in a murine model. J Reprod Immunol 2006; 72 (1-2):85-93.
73. Zhang J, Xu Z, Zhang C, et al. Pyrrolidine dithiocarbamate inhibits nuclear factor-κB pathway activation, and regulates adhesion, migration, invasion and apoptosis of endometriotic stromal cells. Mol Hum Reprod 2011; 17:175-181.
74. Takai E, Taniguchi F, Nakamura K. Parthenolide reduces cell proliferation and prostaglandin E2 [corrected] in human endometriotic stromal cells and inhibits development of endometriosis in the murine model. Fertil Steril 2013; 100:1170-1178.
75. Izawa M, Taniguchi F, Terakawa N, Harada T. Epigenetic aberration of gene expression in endometriosis. Front Biosci (Elite Ed) 2013; 5:900-910.
76. Guo SW. Epigenetics of endometriosis. Mol Hum Reprod 2009; 15:587-607.
77. Wu Y, Guo SW. Peroxisome proliferator-activated receptor-gamma and retinoid X receptor agonists synergistically suppress proliferation of immortalized endometrial stromal cells. Fertil Steril 2009; 91:2142-2147.
78. Lu Y, Nie J, Liu X, et al. Trichostatin A, a histone deacetylase inhibitor, reduces lesion growth and hyperalgesia in experimentally induced endometriosis in mice. Hum Reprod 2010; 25:1014-1025.
79. Liu M, Liu X, Zhang Y, Guo SW. Valproic acid and progestin inhibit lesion growth and reduce hyperalgesia in experimentally induced endometriosis in rats. Reprod Sci 2012; 19:360-373.
80. Flower A, Liu JP, Lewith G, et al. Chinese herbal medicine for endometriosis. Cochrane Database Syst Rev 2012; 16:; CD006568.
81. Ingelmo J, Quereda F, Acién P. Effect of human interferon-alpha-2b on experimental endometriosis in rats: comparison between short and long series of treatment. Eur J Obstet Gynecol Reprod Biol 2013; 167:190-193.
82. Acién P, Quereda F, Campos A, et al. Use of intraperitoneal interferon alpha- 2b therapy after conservative surgery for endometriosis and postoperative medical treatment with depot gonadotropin-releasing hormone analog: a randomized clinical trial. Fertil Steril 2002; 78:705-711.
83. Acién P, Velasco I, Acién M, Quereda F. Treatment of endometriosis with transvaginal ultrasound-guided drainage and recombinant interleukin-2 left in the cysts: a third clinical trial. Gynecol Obstet Invest 2010; 69:203-211.
84. Edelstam G, Sjösten A, Jablonowska B, et al. Pertubation with lidocaine - a nonhormonal, long-term treatment of dysmenorrhea due to endometriosis. Sex Reprod Healthc 2012; 3:93-94.